Due to the potential Canada Post labour disruption, you should use another courier if you want to apply by mail, or apply at a Service Canada Centre or passport office. In preparation for a possible ...

The regulator’s priority review and sBLA approval of the antibody were supported by data from Phase III and Phase II trials.

All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, ...

SCAC, a rare disease, makes up 85% of anal cancer cases. As Incyte CEO Hervé Hoppenot has previously told Fierce Pharma, the company does not expect Zynyz to be a major revenue driver.

The FDA has also approved Zynyz as a single agent for the treatment of adults with locally recurrent or metastatic SCAC who had disease progression on or intolerance to platinum-based chemotherapy.

In the girls SCAC championships in the same location, Oswego freshman Sophia Otokiti and Fulton freshman Audrina Horton also claimed individual crowns.

OpenForm in a DNN module to create end users forms like contact, register, etc. The definition of the form is based on Alpaca json format.

should be given on a Supplemental Form 8 (Open Positions). Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b ...

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

The FDA has approved retifanlimab-dlwr (Zynyz) for the treatment of advanced squamous cell carncinoma of the anal canal (SCAC) as a monotherapy and in combination with chemotherapy. This makes it the ...

ispc compiles a C-based SPMD programming language to run on the SIMD units of CPUs and GPUs; it frequently provides a 3x or more speedup on architectures with 4-wide vector SSE units and 5x-6x on ...

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?